CDXC

ChromaDex Corporation [CDXC] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CDXC Stock Summary

Top 10 Correlated ETFs

CDXC


Top 10 Correlated Stocks

CDXC


In the News

08:32 29 Mar 2024 CDXC

ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter, which ended December 31, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex.

04:08 29 Mar 2024 CDXC

ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #IR--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners 2024 Investor Select Conference. Mr. Fried and Mrs. Gerber will participate in virtual one-on-one meetings throughout the event on Thursday, February 1, 2024. To arrange a meeting with the Chrom.

07:28 29 Mar 2024 CDXC

ChromaDex: Growth At A Reasonable Price

Nutraceuticals and supplements industry is gaining traction due to increasing demand for products that promote well-being. ChromaDex Corporation offers an interesting technology and product, Niagen, which boosts NAD+ levels in the body. ChromaDex's Q3 performance showed substantial sales growth and improvement in gross margin, making it an attractive investment opportunity.

09:02 29 Mar 2024 CDXC

ChromaDex Corporation (CDXC) Q3 2023 Earnings Call Transcript

ChromaDex Corporation (CDXC) Q3 2023 Earnings Call Transcript

08:34 29 Mar 2024 CDXC

ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Bioscience--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, November 8, 2023 at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDe.

08:32 29 Mar 2024 CDXC

ChromaDex Corporation (CDXC) Q2 2023 Earnings Call Transcript

ChromaDex Corporation (NASDAQ:CDXC ) Q2 2023 Earnings Call Transcript August 9, 2023 4:30 PM ET Company Participants Kendall Knysch - Director, Media Relations Rob Fried - Chief Executive Officer Brianna Gerber - Chief Financial Officer Conference Call Participants Ram Selvaraju - H.C. Wainwright Jeff Van Sinderen - B.

08:02 29 Mar 2024 CDXC

ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, August 9, 2023 at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended on June 30, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will.

08:34 29 Mar 2024 CDXC

ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2023 Investor Conference. Mr. Fried and Mrs. Gerber will be participating in virtual one-on-one meetings throughout the event on Thursday, May 18, 2023. To arrange a meeting with the ChromaDex management team, please contact.

06:59 29 Mar 2024 CDXC

ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates

ChromaDex (CDXC) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.11 per share a year ago.

08:32 29 Mar 2024 CDXC

ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Q1Earnings--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, May 10, 2023 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex manage.

CDXC Financial details

Company Rating
Buy
Market Cap
268.1M
Income
-4.37M
Revenue
83.57M
Book val./share
0.38
Cash/share
0.36
Dividend
-
Dividend %
-
Employees
106
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-29.18
Forward P/E
58
PEG
4.04
P/S
1.33
P/B
4.07
P/C
9.67
P/FCF
19.04
Quick Ratio
1.66
Current Ratio
2.43
Debt / Equity
0.12
LT Debt / Equity
0.09
-
-
EPS (TTM)
-0.06
EPS next Y
0.06
EPS next Q
-0.02
EPS this Y
-68.62%
EPS next Y
-198.63%
EPS next 5Y
-288.68%
EPS last 5Y
-34.58%
Revenue last 5Y
12.54%
Revenue Q/Q
8.73%
EPS Q/Q
-111.72%
-
-
-
-
SMA20
100%
SMA50
300%
SMA100
300%
Inst Own
11.36%
Inst Trans
0.76%
ROA
-7%
ROE
-14%
ROC
-0.2%
Gross Margin
60%
Oper. Margin
-8%
Profit Margin
-5%
Payout
-
Shs Outstand
75.31M
Shs Float
44.6M
-
-
-
-
Target Price
-
52W Range
1.25-3.59
52W High
+16%
52W Low
+248%
RSI
73
Rel Volume
2.68
Avg Volume
181.1K
Volume
486.24K
Perf Week
8.75%
Perf Month
114.81%
Perf Quarter
152.17%
Perf Half Y
143.36%
-
-
-
-
Beta
1.872
-
-
Volatility
0.14%, 0.83%
Prev Close
0%
Price
3.48
Change
-5.18%

CDXC Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.810.9711.051.11
Net income per share
-0.55-0.3-0.38-0.21-0.07
Operating cash flow per share
-0.36-0.17-0.36-0.220.09
Free cash flow per share
-0.37-0.18-0.37-0.220.09
Cash per share
0.330.270.420.290.36
Book value per share
0.360.270.470.420.38
Tangible book value per share
0.340.250.460.410.37
Share holders equity per share
0.360.270.470.420.38
Interest debt per share
0.020.030.070.060.04
Market cap
245.91M293.12M251.27M115.78M107.23M
Enterprise value
228.82M278.26M227.95M99.8M83.18M
P/E ratio
-7.81-15.86-9.83-8.01-21.71
Price to sales ratio
5.314.953.731.611.28
POCF ratio
-12.03-27.65-10.4-7.6715.23
PFCF ratio
-11.6-27.29-10.23-7.515.55
P/B Ratio
12.0317.857.924.043.77
PTB ratio
12.0317.857.924.043.77
EV to sales
4.944.73.381.391
Enterprise value over EBITDA
-7.31-14.02-8.42-5.36-428.77
EV to operating cash flow
-11.2-26.25-9.43-6.6111.81
EV to free cash flow
-10.8-25.9-9.28-6.4712.07
Earnings yield
-0.13-0.06-0.1-0.12-0.05
Free cash flow yield
-0.09-0.04-0.1-0.130.06
Debt to equity
0.080.10.150.150.12
Debt to assets
0.040.040.080.080.06
Net debt to EBITDA
0.550.750.860.86123.96
Current ratio
2.231.962.782.612.4
Interest coverage
36.95-279.63-492.24-6.21K0
Income quality
0.640.530.890.91-1.43
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.740.510.540.390.3
Research and developement to revenue
0.10.060.060.070.06
Intangibles to total assets
0.030.030.010.010.01
Capex to operating cash flow
0.040.010.020.02-0.02
Capex to revenue
-0.020-0.0100
Capex to depreciation
-0.49-0.09-0.25-0.18-0.09
Stock based compensation to revenue
0.150.120.090.080.06
Graham number
2.111.352.011.40.75
ROIC
-1.28-0.93-0.62-0.44-0.06
Return on tangible assets
-0.81-0.5-0.45-0.27-0.09
Graham Net
0.110.040.190.120.16
Working capital
18.46M15.74M31.29M28.7M28.91M
Tangible asset value
19.13M15.34M30.87M28M27.95M
Net current asset value
13.72M10.29M22.79M21.18M23.03M
Invested capital
0.080.10.150.150.12
Average receivables
3.3M2.43M3.96M6.85M6.86M
Average payables
9.59M9.54M9.93M10.05M9.96M
Average inventory
9.89M11.61M12.64M14.14M14.6M
Days sales outstanding
17.1516.5928.2842.9722.86
Days payables outstanding
171.21143.74146.55120.77113.9
Days of inventory on hand
205.16177.8191.24183.13161.68
Receivables turnover
21.282212.918.4915.97
Payables turnover
2.132.542.493.023.2
Inventory turnover
1.782.051.911.992.26
ROE
-1.54-1.13-0.81-0.5-0.17
Capex per share
-0.010-0.0100

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.280.30.270.260.28
Net income per share
0.01-0.02-0.03-0.010
Operating cash flow per share
00.040.040.010.01
Free cash flow per share
-0.010.040.0400.01
Cash per share
0.270.310.350.350.36
Book value per share
0.390.370.360.360.38
Tangible book value per share
0.380.370.350.360.37
Share holders equity per share
0.390.370.360.360.38
Interest debt per share
0.060.060.050.050.04
Market cap
124.12M114.44M117.7M109.57M107.22M
Enterprise value
108.13M95.36M95.38M86.74M83.17M
P/E ratio
46.11-21.51-13.43-28.56235.14
Price to sales ratio
5.915.075.795.625.06
POCF ratio
-378.440.9935.88276.7186.8
PFCF ratio
-248.2342.3735.99296.14193.89
P/B Ratio
4.334.084.344.013.77
PTB ratio
4.334.084.344.013.77
EV to sales
5.154.234.694.453.92
Enterprise value over EBITDA
-74.88-48.46-50.95-124.09137.48
EV to operating cash flow
-329.6734.1629.08219.04144.9
EV to free cash flow
-216.2635.3129.17234.44150.41
Earnings yield
0.01-0.01-0.02-0.010
Free cash flow yield
00.020.0300.01
Debt to equity
0.150.150.150.140.12
Debt to assets
0.080.080.070.070.06
Net debt to EBITDA
11.079.6911.9232.66-39.75
Current ratio
2.612.532.432.432.4
Interest coverage
72.2-29.82-18.53-6.10
Income quality
0.23-1.47-1.5-0.415.04
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.290.280.360.30.26
Research and developement to revenue
0.060.050.070.060.05
Intangibles to total assets
0.010.010.010.010.01
Capex to operating cash flow
0.52-0.030-0.07-0.04
Capex to revenue
-0.010000
Capex to depreciation
-0.38-0.21-0.02-0.06-0.06
Stock based compensation to revenue
0.060.060.070.060.05
Graham number
0.280.390.490.320.11
ROIC
0.02-0.04-0.07-0.030.01
Return on tangible assets
0.01-0.03-0.04-0.020
Graham Net
0.120.140.140.150.16
Working capital
28.7M28.14M27.32M27.74M28.91M
Tangible asset value
28M27.39M26.56M26.76M27.95M
Net current asset value
21.18M20.81M20.36M21.01M23.03M
Invested capital
0.150.150.150.140.12
Average receivables
6.61M8.85M7.67M5.86M5.42M
Average payables
9.4M9.32M9.49M9.61M9.72M
Average inventory
15.16M13.29M11.94M12.3M13.57M
Days sales outstanding
36.3636.7927.0925.8622.22
Days payables outstanding
97.0189.13113.32109.99111.5
Days of inventory on hand
147.1118.58135.25150.96158.28
Receivables turnover
2.482.453.323.484.05
Payables turnover
0.931.010.790.820.81
Inventory turnover
0.610.760.670.60.57
ROE
0.02-0.05-0.08-0.040
Capex per share
00000

CDXC Frequently Asked Questions

What is ChromaDex Corporation stock symbol ?

ChromaDex Corporation is a US stock , located in Los angeles of Ca and trading under the symbol CDXC

What is ChromaDex Corporation stock quote today ?

ChromaDex Corporation stock price is $3.48 today.

Is ChromaDex Corporation stock public?

Yes, ChromaDex Corporation is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap